Post by The Ritedose Corporation

The difference sterility makes. Earlier this year, the US FDA recalled three million multidose bottles of eye drops, citing sterility issues. Inadequate documentation, unrealistic testing, and even operators reaching into filling lines with arms and hands. A 2023 FDA warning letter apparently wasn’t enough. This is beyond a compliance failure — it's a patient safety crisis, especially in the hypersensitive world of ophthalmic treatments. At Ritedose, we take the necessary steps not only to prevent sources of infection, but also to take time and effort to document those steps and do the testing to ensure our products are delivered to patients who need them, safely and reliably. Learn more from our latest blog post here:https://loom.ly/WX-H5dI